The Dark Side of Cell Fusion - PubMed
- ️Fri Jan 01 2016
Review
The Dark Side of Cell Fusion
Daniel Bastida-Ruiz et al. Int J Mol Sci. 2016.
Abstract
Cell fusion is a physiological cellular process essential for fertilization, viral entry, muscle differentiation and placental development, among others. In this review, we will highlight the different cancer cell-cell fusions and the advantages obtained by these fusions. We will specially focus on the acquisition of metastatic features by cancer cells after fusion with bone marrow-derived cells. The mechanism by which cancer cells fuse with other cells has been poorly studied thus far, but the presence in several cancer cells of syncytin, a trophoblastic fusogen, leads us to a cancer cell fusion mechanism similar to the one used by the trophoblasts. The mechanism by which cancer cells perform the cell fusion could be an interesting target for cancer therapy.
Keywords: cancer; cell fusion; drug resistance; metastasis; syncytin.
Figures

Multinucleated human ovarian cancer cell isolated from malignant ascites. The cells are labeled with DAPI (nucleus, blue) and Phalloidin (actin, red) and observed by confocal microscopy at magnification 400×. Scale bars: 20 µm. The white arrow indicates the multinucleated cell.

Cell fusion mediated by syncytin 1. (A) Schematic portrait of syncytin 1 structure. The signal peptide domain is represented in light blue. The surface unit (SU) is represented in yellow and contains a receptor binding domain (RBD; SDGGGX2DX2R) and a CXXC motif. The transmembrane unit (TM) contains a fusion peptide represented in red, heptad repeats 1 (HR1) represented in purple, heptad repeats 2 (HR2) represented in pink, a transmembrane domain represented in black, an intracytoplasmic domain represented in green and a CX6CC domain. Between the SU and the TM is a furin cleavage site (RNKR) represented in light red. The Y indicate N-glycosylation sites and numbers indicate the amino acid position. A disulfide bond is formed between the CXXC motif of SU and the CX6CC domain of TM; (B) Schematic representation of syncytin 1-dependent cell fusion. (a) Resting stage; (b) RBD (yellow) binding to the hASCT2 receptor (light green); (c) Disulfide bond breaking and removing of SU domains, producing a conformational change in syncytin 1 protein leading to the insertion of the fusion peptide (red) into the cell membrane; (d) Assembly of HR2 (pink) and HR1 (purple); (e) Final stage with the membranes in close proximity and initiation of membrane bending. Adapted from [106,107].
Similar articles
-
Interferon-induced transmembrane proteins inhibit cell fusion mediated by trophoblast syncytins.
Zani A, Zhang L, McMichael TM, Kenney AD, Chemudupati M, Kwiek JJ, Liu SL, Yount JS. Zani A, et al. J Biol Chem. 2019 Dec 27;294(52):19844-19851. doi: 10.1074/jbc.AC119.010611. Epub 2019 Nov 17. J Biol Chem. 2019. PMID: 31735710 Free PMC article.
-
Reconstitution of Fusion-Competent Human Placental Fusogen Syncytin-2.
Xu L, Sun S. Xu L, et al. J Membr Biol. 2022 Dec;255(6):723-732. doi: 10.1007/s00232-022-00242-0. Epub 2022 May 20. J Membr Biol. 2022. PMID: 35596004
-
Tang C, Tang L, Wu X, Xiong W, Ruan H, Hussain M, Wu J, Zou C, Wu X. Tang C, et al. J Biol Chem. 2016 Mar 11;291(11):5611-5622. doi: 10.1074/jbc.M115.700336. Epub 2016 Jan 14. J Biol Chem. 2016. PMID: 26769961 Free PMC article.
-
Huppertz B, Borges M. Huppertz B, et al. Methods Mol Biol. 2008;475:135-47. doi: 10.1007/978-1-59745-250-2_8. Methods Mol Biol. 2008. PMID: 18979242 Review.
-
Syncytins expressed in human placental trophoblast.
Roberts RM, Ezashi T, Schulz LC, Sugimoto J, Schust DJ, Khan T, Zhou J. Roberts RM, et al. Placenta. 2021 Sep 15;113:8-14. doi: 10.1016/j.placenta.2021.01.006. Epub 2021 Jan 15. Placenta. 2021. PMID: 33504453 Free PMC article. Review.
Cited by
-
Nucleic Acid Delivery with Red-Blood-Cell-Based Carriers.
Della Pelle G, Kostevšek N. Della Pelle G, et al. Int J Mol Sci. 2021 May 17;22(10):5264. doi: 10.3390/ijms22105264. Int J Mol Sci. 2021. PMID: 34067699 Free PMC article. Review.
-
Cell Fusion in Malignancy: A Cause or Consequence? A Provocateur or Cure?
Platt JL, Cascalho M. Platt JL, et al. Cells. 2019 Jun 14;8(6):587. doi: 10.3390/cells8060587. Cells. 2019. PMID: 31207918 Free PMC article. Review.
-
Lymphoproliferative Syndromes Associated with Human Herpesvirus-6A and Human Herpesvirus-6B.
Eliassen E, Krueger G, Luppi M, Ablashi D. Eliassen E, et al. Mediterr J Hematol Infect Dis. 2018 May 1;10(1):e2018035. doi: 10.4084/MJHID.2018.035. eCollection 2018. Mediterr J Hematol Infect Dis. 2018. PMID: 29755712 Free PMC article. Review.
-
Cell membrane modulation as adjuvant in cancer therapy.
Zalba S, Ten Hagen TL. Zalba S, et al. Cancer Treat Rev. 2017 Jan;52:48-57. doi: 10.1016/j.ctrv.2016.10.008. Epub 2016 Nov 9. Cancer Treat Rev. 2017. PMID: 27889637 Free PMC article. Review.
-
Weiler J, Mohr M, Zänker KS, Dittmar T. Weiler J, et al. Cell Commun Signal. 2018 Apr 10;16(1):14. doi: 10.1186/s12964-018-0226-1. Cell Commun Signal. 2018. PMID: 29636110 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources